



NEWPORT GENERIC DEALS MODULE

INTELLIGENCE AT YOUR FINGERTIP FOR YOUR NEXT DEAL

HOW TO SUBSCRIBE

The *Newport Generic Deals Module* is an optional subscription module that may be added on a per-seat basis to *Newport Premium™*, *Newport Global™*, and *Newport Sourcing™* product configurations for an additional annual charge. A subscription to a base system is required before purchasing this module. To get a quotation, contact your account manager or visit science.thomsonreuters.com/info/sales

WHAT GENERIC DEALS CAN HELP YOU DO

- Seek out partners and acquisition targets
- Anticipate moves by your competitors
- Improve and streamline your partner selection process and sourcing decisions
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets

HOW YOU BENEFIT

- Monthly intelligence updates
- Simple web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

GAIN A COMPETITIVE EDGE BY HAVING ALL THE FACTS AT HAND

The *Newport Generic Deals Module* provides you with all the facts you need to make a deal, choose a partner, scout the competition, or look for your next acquisition.

Seamlessly integrated into *Newport Sourcing™*, *Newport Global™* and *Newport Premium™*, *Generic Deals* contains detailed intelligence from Thomson Reuters on thousands of merger and acquisition, development, supply, manufacturing, joint venture, patent settlement, and authorized generic deals involving generic companies worldwide since 1999.

For each deal, and where applicable, you can explore the parties involved, their geographic location, announcement and transaction dates, source attribution, dollar value and percentage stake, the deal type and status, and a summary description.

A new focused search enables you to conduct comprehensive analysis of global generic deal-making activity. Email alerts advise you of the latest changes to deals being pursued and closed by the generic

industry worldwide.

GENERIC DEALS HELPS YOUR STRATEGIC PLANNING TEAM TO:

- Improve, inform and streamline your partner selection process
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets
- Anticipate moves by your competitors

GENERIC DEALS HELPS YOUR BUSINESS DEVELOPMENT TEAM TO:

- Profile partners for acquisition, alliances, licensing, or supply and manufacturing deals
- Improve your product selection process and sourcing decisions

GENERIC DEALS ALSO AIDS COMPANY AND PATENT INTELLIGENCE

Generic Deals can help your company intelligence team to monitor deal-making activity by hundreds of companies. It can also help your product intelligence team to track and monitor deal-making around products of interest.

Scientific Head Offices

Americas

Philadelphia
+1 800 336 4474
+1 215 386 0100

Europe, Middle East and Africa

London +44 20 7433 4000

Asia Pacific

Singapore +65 6411 6888
Tokyo +81 3 5218 6500

For a complete office list visit:
scientific.thomsonreuters.com/contact

PH0906130e

Copyright © 2009 Thomson Reuters

Acquirer/Principal Company	Country	Target/Partner Company	Country	Deal Type	Status
Novartis AG	Switzerland	Hexal AG	Germany	MA	Completed
Novartis AG	Switzerland	Eon Labs Inc	US	MA	Completed
Novartis AG	Switzerland	Eon Labs Inc	US	MA	Completed
Novartis AG	Switzerland	Bristol-Myers Squibb Co-US Consumer Medicines Business	US	MA	Completed
Novartis Animal Health US Inc	US	Boehringer Ingelheim Vetmedica-Denagard Product Line	US	MA	Completed
Sandoz Farmaceutica Lda	Portugal	Bexal-Produtos Farmaceuticos SA	Portugal	MA	Completed
Novartis AG	Switzerland	Chiron Corp	US	MA	Completed
Novartis Pharma AG	Switzerland	NovoTec Pharma Plc	UK	MA	Unconditional
Novartis Animal Health KK	Japan	LINECH Animal Health Co Ltd	Japan	MA	Completed
Novartis AG	Switzerland	Thommen Medical AG	Switzerland	MA	Completed
Novartis AG	Switzerland	Intercell AG	Austria	MA	Completed
Novartis AG	Switzerland	Akzon Inc	US	MA	Completed

New Deals pages for corporate groups display mergers and acquisitions, manufacturing and marketing alliances, litigation settlements, and other deals from the past 10 years.

Acquirer/Principal Company Name	Actavis Group HF
Acquirer/Principal Company Country	Iceland
Target/Partner Company Name	Endo Pharmaceuticals Holdings Inc
Target/Partner Company Country	Iceland
Date Announced	20 Feb 2009
Date Effective	
Date Terminated	
Value (\$M)	
Type	Patent Litigation Settlement
Products	oxymorphone hydrochloride

Summary
In February 2009, Actavis entered into a litigation settlement agreement with Endo Pharmaceuticals and Penwest Pharmaceutical regarding the product (oxymorphone hydrochloride) Extended Release Tablets CII.

Deal detail pages highlight the involved parties, dates, and values, and provide a short synopsis of the deal.



THOMSON REUTERS™